oncolytic virus engineering

Candel Therapeutics is a clinical-stage biotech company developing off-the-shelf viral immunotherapies for solid tumors. Its lead therapy, aglatimagene besadenovec (CAN-2409), is an adenoviral gene construct encoding HSV-thymidine kinase that triggers immunogenic cell death and CD8+ T cell-mediated anti-tumor immunity. The company also develops linoserpaturev, a replication-competent HSV engineered for selective killing of cancer cells. Phase 3 data in prostate cancer and active trials in lung and brain cancer are cited.

Read more

clinical trialsgene therapyviral immunotherapy